Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 3121 AL 3135

The Efficacy of Sertraline, Escitalopram, and Nicergoline in the Treatment of Depression and Apathy in Alzheimer's Disease: The Okayama Depression and Apathy Project (ODAP)

Takemoto M, Ohta Y, Hishikawa N, Yamashita T, Nomura E, Tsunoda K, Sasaki R, Tadokoro K, Matsumoto N, Omote Y, Abe K.

J Alzheimers Dis. 2020;76(2):769-772. doi: 10.3233/JAD-200247.

Meta-analysis of Ginkgo biloba Preparation for the Treatment of Alzheimer's Disease

Liao Z, Cheng L, Li X, Zhang M, Wang S, Huo R.

Clin Neuropharmacol. 2020 Jul/Aug;43(4):93-99. doi: 10.1097/WNF.0000000000000394.

Calcium Channel Blockers: A Possible Potential Therapeutic Strategy for the Treatment of Alzheimer's Dementia Patients with SARS-CoV-2 Infection

Danta CC.

ACS Chem Neurosci. 2020 Aug 5;11(15):2145-2148. doi: 10.1021/acschemneuro.0c00391. Epub 2020 Jul 14.

Quinones as preventive agents in Alzheimer's diseases: focus on NLRP3 inflammasomes

Chen DB, Gao HW, Peng C, Pei SQ, Dai AR, Yu XT, Zhou P, Wang Y, Cai B.

J Pharm Pharmacol. 2020 Nov;72(11):1481-1490. doi: 10.1111/jphp.13332. Epub 2020 Jul 15.

Effect of Rotigotine vs Placebo on Cognitive Functions Among Patients With Mild to Moderate Alzheimer Disease: A Randomized Clinical Trial

Koch G, Motta C, Bonnì S, Pellicciari MC, Picazio S, Casula EP, Maiella M, Di Lorenzo F, Ponzo V, Ferrari C, Scaricamazza E, Caltagirone C, Martorana A.

JAMA Netw Open. 2020 Jul 1;3(7):e2010372. doi: 10.1001/jamanetworkopen.2020.10372.

Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial

Arellanes IC, Choe N, Solomon V, He X, Kavin B, Martinez AE, Kono N, Buennagel DP, Hazra N, Kim G, D'Orazio LM, McCleary C, Sagare A, Zlokovic BV, Hodis HN, Mack WJ, Chui HC, Harrington MG, Braskie MN, Schneider LS, Yassine HN.

EBioMedicine. 2020 Sep;59:102883. doi: 10.1016/j.ebiom.2020.102883. Epub 2020 Jul 17.

Safety and target engagement profile of two oxaloacetate doses in Alzheimer's patients

Vidoni ED, Choi IY, Lee P, Reed G, Zhang N, Pleen J, Mahnken JD, Clutton J, Becker A, Sherry E, Bothwell R, Anderson H, Harris RA, Brooks W, Wilkins HM, Mosconi L, Burns JM, Swerdlow RH.

Alzheimers Dement. 2021 Jan;17(1):7-17. doi: 10.1002/alz.12156. Epub 2020 Jul 27.

Discontinuation of cholinesterase inhibitor treatment in institutionalised patients with advanced dementia

García-García R, Calleja-Hernández MÁ.

Eur J Hosp Pharm. 2022 May;29(3):145-150. doi: 10.1136/ejhpharm-2019-002106. Epub 2020 Jul 28.

Brain Tau Imaging: Food and Drug Administration Approval of (18)F-Flortaucipir Injection

Mattay VS, Fotenos AF, Ganley CJ, Marzella L.

J Nucl Med. 2020 Oct;61(10):1411-1412. doi: 10.2967/jnumed.120.252254. Epub 2020 Aug 4.

Galantamine-Memantine combination in the treatment of Alzheimer's disease and beyond

Koola MM.

Psychiatry Res. 2020 Nov;293:113409. doi: 10.1016/j.psychres.2020.113409. Epub 2020 Aug 18.

A phase II randomized trial of sodium oligomannate in Alzheimer's dementia

Wang T, Kuang W, Chen W, Xu W, Zhang L, Li Y, Li H, Peng Y, Chen Y, Wang B, Xiao J, Li H, Yan C, Du Y, Tang M, He Z, Chen H, Li W, Lin H, Shi S, Bi J, Zhou H, Cheng Y, Gao X, Guan Y, Huang Q, Chen K, Xin X, Ding J, Geng M, Xiao S.

Alzheimers Res Ther. 2020 Sep 14;12(1):110. doi: 10.1186/s13195-020-00678-3.

Association of sex and APOE ε4 with brain tau deposition and atrophy in older adults with Alzheimer's disease

Yan S, Zheng C, Paranjpe MD, Li J, Benzinger TLS, Lu J, Zhou Y.

Theranostics. 2020 Aug 21;10(23):10563-10572. doi: 10.7150/thno.48522. eCollection 2020.

Worsening behavioural and psychological symptoms of dementia during the coronavirus disease 2019 pandemic

Shea YF, Shum CK, Wan WH, Chan MMK.

Psychogeriatrics. 2020 Nov;20(6):916-917. doi: 10.1111/psyg.12608. Epub 2020 Sep 14.

Pattern of treatment of behavioural and psychological symptoms of dementia and pain: evidence on pharmacoutilization from a large real-world sample and from a centre for cognitive disturbances and dementia

Scuteri D, Vulnera M, Piro B, Bossio RB, Morrone LA, Sandrini G, Tamburin S, Tonin P, Bagetta G, Corasaniti MT.

Eur J Clin Pharmacol. 2021 Feb;77(2):241-249. doi: 10.1007/s00228-020-02995-w. Epub 2020 Sep 15.

The development of new method to differentiate between Dementia with Lewy bodies and Alzheimer's disease by cerebral perfusion SPECT-comparison to CIScore

Honda G, Nagamachi S, Nonokuma M, Takano K, Kuwabara Y, Yoshimitsu K, Iida H, Ogomori K, Kawasaki H, Tsuboi Y.

Jpn J Radiol. 2021 Feb;39(2):198-205. doi: 10.1007/s11604-020-01041-0. Epub 2020 Sep 16.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias